Keros Therapeutics (NASDAQ:KROS) Shares Gap Down Following Analyst Downgrade

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) gapped down prior to trading on Monday after Oppenheimer lowered their price target on the stock from $102.00 to $63.00. The stock had previously closed at $18.83, but opened at $18.25. Oppenheimer currently has an outperform rating on the stock. Keros Therapeutics shares last traded at $19.56, with a volume of 291,495 shares trading hands.

Other equities analysts also recently issued reports about the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Keros Therapeutics in a research note on Friday, November 22nd. Scotiabank decreased their price target on shares of Keros Therapeutics from $77.00 to $44.00 and set a “sector outperform” rating on the stock in a research note on Friday. Bank of America reduced their price objective on shares of Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating on the stock in a research note on Thursday, September 12th. Wells Fargo & Company increased their price objective on shares of Keros Therapeutics from $88.00 to $111.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 11th. Finally, Guggenheim downgraded shares of Keros Therapeutics from a “buy” rating to a “neutral” rating in a research note on Monday. Four equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to MarketBeat.com, Keros Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $81.33.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Charles Schwab Investment Management Inc. lifted its holdings in shares of Keros Therapeutics by 14.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 260,120 shares of the company’s stock worth $15,105,000 after acquiring an additional 32,492 shares during the last quarter. Assenagon Asset Management S.A. bought a new position in shares of Keros Therapeutics in the second quarter worth about $1,118,000. Intech Investment Management LLC bought a new position in shares of Keros Therapeutics in the third quarter worth about $603,000. Bank of New York Mellon Corp lifted its holdings in shares of Keros Therapeutics by 18.8% in the second quarter. Bank of New York Mellon Corp now owns 118,388 shares of the company’s stock worth $5,410,000 after acquiring an additional 18,755 shares during the last quarter. Finally, Point72 Asset Management L.P. lifted its holdings in shares of Keros Therapeutics by 155.9% in the third quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company’s stock worth $55,025,000 after acquiring an additional 577,220 shares during the last quarter. Institutional investors own 71.56% of the company’s stock.

Keros Therapeutics Price Performance

The business’s fifty day moving average price is $58.29 and its 200 day moving average price is $52.50. The stock has a market cap of $786.65 million, a P/E ratio of -3.73 and a beta of 1.20.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). The business had revenue of $0.39 million during the quarter. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. Keros Therapeutics’s revenue was up 4750.0% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.33) EPS. On average, analysts predict that Keros Therapeutics, Inc. will post -5.26 earnings per share for the current fiscal year.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.